The difficult manufacturing process for follow-on biologics may discourage companies
This article was originally published in The Gold Sheet
Executive Summary
Doug Long, vice president of industry relations for IMS Health, made this prediction at a recent policy meeting sponsored by the Generic Pharmaceutical Association in Washington. Long asserted that while the EU currently has a regulatory approval system for follow-on biologics and will be ahead of the U.S. in developing these products, "U.S. manufacturers will not be far behind." And two key House health legislators, reps. Frank Pallone, D-N.J., and Henry Waxman, D-Calif., asserted at the meeting that Congress will enact an approval pathway for generic biologics this year
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.